Keizman Eitan, Tejman-Yarden Shai, Hubara Evyatar, Illouz Shay, Katz Uriel, Mishaly David, Serraf Alain E, Pollak Uri
Department of Cardiac Surgery, The Leviev Cardiothoracic and Vascular Center, Sheba Medical Center, Ramat-Gan 5266202, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
J Clin Med. 2024 Jun 27;13(13):3761. doi: 10.3390/jcm13133761.
The aim of this study was to evaluate the natural history of patients after mitral valve intervention in the pediatric age. This is a retrospective study including all patients who underwent mitral valve surgery from 1998 to 2022. The patients' surgical reports, postoperative records, and ambulatory visits were reviewed. The endpoints of the study were survival and freedom from mitral valve reoperation. Of the 70 patients included in the cohort, 61 patients (86.7%) had congenital mitral valve disease, of whom 46 patients (75.4%) had a predominantly mitral regurgitation lesion, and 15 patients (24.6%) had a predominantly mitral stenosis. In the mitral regurgitation group, all of the patients underwent valve repair with an operative mortality of one patient (2.1%), and with median follow-up of 4 years (range, 0.5-13 years), there was 4.3% mortality ( = 2) and 71.2% freedom from reoperation. In the mitral stenosis group, 11 patients underwent mitral valve repair, and 4 patients underwent valve replacement. There was an operative mortality of two patients (13.3%). With a 2-year median follow-up (range: 0.1-23 years), there were no additional mortality cases in the mitral stenosis group. All three patients who survived primary mitral valve replacement (100%) and four patients who survived a primary repair (40.0%) underwent reoperation. This study demonstrates encouraging outcomes for mitral valve repair. The mortality of patients with congenital mitral valve disease may also be related to a difficult postoperative course, rather than the MV lesion itself.
本研究的目的是评估小儿二尖瓣干预术后患者的自然病史。这是一项回顾性研究,纳入了1998年至2022年期间所有接受二尖瓣手术的患者。回顾了患者的手术报告、术后记录和门诊就诊情况。研究的终点是生存和免于二尖瓣再次手术。在该队列纳入的70例患者中,61例(86.7%)患有先天性二尖瓣疾病,其中46例(75.4%)主要为二尖瓣反流病变,15例(24.6%)主要为二尖瓣狭窄。在二尖瓣反流组中,所有患者均接受了瓣膜修复,手术死亡率为1例(2.1%),中位随访4年(范围0.5 - 13年),死亡率为4.3%(= 2),免于再次手术率为71.2%。在二尖瓣狭窄组中,11例患者接受了二尖瓣修复,4例患者接受了瓣膜置换。手术死亡率为2例(13.3%)。中位随访2年(范围:0.1 - 23年),二尖瓣狭窄组无额外死亡病例。所有3例原发性二尖瓣置换术后存活的患者(100%)和4例原发性修复术后存活的患者(40.0%)均接受了再次手术。本研究表明二尖瓣修复的结果令人鼓舞。先天性二尖瓣疾病患者的死亡率可能也与术后病程困难有关,而非二尖瓣病变本身。